Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If this is repeated in the study, there will be a great spike in shares. Actually montelukast was also a successful in seasonal allergies as well as it's intended use for asthmatics.
Gary rags up to their old games. So funny
It's called montelukast. Nobody said it will succeed, but has shown excellent results on lab rats. That's no fairy tale.
You don't tax loss sell if a stock is hitting highs
Manipulation. Bring down the price creates tax loss selling. One feeds off the other. Than shares are picked on the cheap. Let's see what singular say's Wednesday morning. As this is then the last month for tax loss you can bet they will try to bring it down to create these opportunities I stated in the beginning. Unless management has a surprise deal on Wednesday for tadalafil and smokes the manipulators. If not, than the Canadians can move more shares in their tfsa accounts in 2017.
From the latest conference call Finally, on Tadalafil, the manufacturing of sedition batches is ongoing. The submission or resubmission of the 505(b)(2) NDA is scheduled for the second quarter of 2017 and the U.S. launch of the product is scheduled for the second quarter of 2018. Again that product is mostly IP driven at this point, the substance patent as I reported before will expire in November 2017. There are besides the substance patent three more Orange Book patents protecting the product. Now two of those products were recently invalidated through a so-called IPR and IntelGenx has earlier this year submitted an IPR with the objective of invalidating at third and last Orange Book patent.
I can only report qualitatively at this point that we are extremely confident that the IPR will be successful meaning that we will be able to invalidate that patent and hence, we continue to anticipate that we will launch the product in the second quarter of 2018. So having said this, I would now like to turn the call over to Andre who will review our Q3 financial results. Seems like a lot of lies being spread by certain board members from the Yahoo message board. To be expected and as intelgenx picks up the pace more to come. It will help me put more shares into my tfsa account. Thank you. Yy
Benign Prostatic Hyperplasia Therapeutics Market grows with Increased Awareness for Prostate Cancer and Other Urological Disorders
DECEMBER 7TH, 2016 TRANSPARENCY MARKET RESEARCH RELEASES
Benign-Prostatic-HyperplasiaBenign prostatic hyperplasia (BPH) or benign prostatic hypertrophy, is a urological disorder that involves proliferation of the cellular components of the prostrate. BPH is the most common form of neoplasm in men. BPH results in the formation of large nodes and nodules in the periurethral region of the prostate. The significantly large nodules compresses the urethral canal that causes to partial or complete urinary tract obstruction which inhibits the normal flow of urine. Obstruction in the urinary tract further leads to complications such as urinary retention, urinary tract infections and urinary hesitancy.
Forthcoming Projections for the Market of Benign Prostatic Hyperplasia Therapeutics at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1872
Some of the medical therapies used for the treatment of BPH are as follows:
> Alpha-Blockers
> 5- Alpha-reductase inhibitors (5-ARIs)
> Alpha-Adrenergic Blockers
> Phosphodiesterase-5 Enzyme Inhibitors
> Anticholinergic Agents
> Nonselective alpha-blockers
Some of the surgical interventions used of the treatment of BPH are as follows:
> Holmium Laser Resection of the Prostate (HoLRP)
> Open prostatectomy
> Photoselective vaporization of the prostate (PVP)
> Transurethral holmium laser ablation of the prostate (HoLAP)
> Transurethral resection of the prostate (TURP)
> Transurethral vaporization of the prostate (TUVP)
> Transurethral incision of the prostate (TUIP)
Geographically, North America is the leading market due to high prevalence rate of benign prostatic hyperplasia and lower urinary tract symptoms (LUTS). Various studies reports that 90% of men in the U.S., aged between 45 and 80 years suffer from some type of LUTS and approximately 14 million men in the U.S. have symptoms of BPH. Asia-Pacific is also expected to witness a significant growth due to the rise in various urological disorders and complications. However, BPH tends to be more progressive in African-American men owing to the presence of high testosterone level in their body.
Rise in geriatric population is expected to be one of the major driver that might drive the market. Additionally, increased awareness for prostate cancer and other urological disorders, are also expected to fuel the growth of the global BPH therapeutics market. However, high adoption rate of minimally invasive surgeries such as transurethral microwave thermotherapy (TUMT), laparoscopic prostatectomy and transurethral needle ablation (TUNA) might impede the growth of the BPH therapeutics market.
Some of the key players in the benign prostatic hyperplasia (BPH) therapeutics Market are AEternaZentaris Inc., Astellas Pharma Inc., Eli Lilly and Company, EndoCeutics, Inc., IntelGenx Technologies Corp., Ipsen S.A., Nymox Pharmaceutical Corporation, Protox Therapeutics Inc. and Quest PharmaTech Inc.
Easy double 2017. Non believers should sell now. Save you the anxiety
It's done for competitive reasons.seems it's the world of generics, which does make sense
You and the rest of us are not idiots. Wait come March. Patience.
Easily confused. Now we wait for a deal on tadalafil. It seems like chemo may be a good partner. I would not be surprised if they make a bid for us in the future
Sold 25k and still holds 88k
What will be big will be a deal from Eli Lilly. I give it a 50%
The next couple of months should be telling
Do YOU find it coincidence they sign with us for tadalafil among others also going for generic launch. But we also have a dementia drug in testing phase 2. As they had knowledge their Alzheimer's drug was failing.
ELI Lilly to keep intelgenx on a short leash due to Lilly's Alzheimer's drug failure and intelgenx montelukast. This can get very interesting. Figure's why a deal was set for tadalafil.
I would not be surprised if a deal is set with Eli Lilly. That would be great
Life expectancy has increased dramatically in the last few decades, particularly in the most developed countries. And that’s a wonderful thing. But this increase has brought a number of new challenges in health and healthcare, specifically in age-related conditions, such as neurological conditions. One of the great challenges in medical research is, therefore, to find a way to keep up with the healthcare demands of an ageing population. So, whenever a new promising therapy emerges, it is always worth a shout out.
Age-associated diseases have a higher prevalence than ever and consequently, a huge social impact. The brain goes through a number of changes as it ages: our cognitive skills decay, while the risk of dementia and neurodegenerative diseases increases.
As it ages, the brain loses its ability to generate new cells, while the existing cells lose functional properties. The blood-brain barrier, the protective boundary that separates the blood from the extracellular fluid in the central nervous system, loses power and becomes less selective, allowing for more circulating (and potentially damaging) molecules to reach the brain. And the blood is an important factor in ageing: it has been shown that exposing the aged brain to young blood can reverse some of the age-associated changes; the opposite is also true – old blood can cause a premature ageing of a young brain.
One of the main driving forces of age-related neurological conditions is neuroinflammation. The aged brain produces increased levels of pro-inflammatory molecules and loses some ability to counterbalance these changes through anti-inflammatory mechanisms. Also, inflammatory mediators in the blood gain an easier access to the brain.
In theory, delaying or even reversing these neuroinflammatory changes could potentially rejuvenate the brain and help preserve or even improve cognitive functions in elderly people. And that is exactly what a European research group aimed at in a study recently published in Nature Communications.
This group of researchers from Austria, Germany, Italy and Croatia presented a new therapy that, according to their own words, can “functionally rejuvenate the aged but otherwise healthy brain”. And the therapeutic agent is probably surprising: it’s an anti-asthmatic drug named montelukast.
The authors had previously identified a molecule involved in asthma pathology as being elevated in ageing, contributing to neuroinflammation and cognitive impairment. This led them to the hypothesis that other mechanisms originally related to peripheral inflammatory conditions such as asthma might affect the central nervous system, potentially contributing to degenerative processes.
Leukotrienes are a group of molecules that mediate inflammatory reactions associated with increased vascular permeability. Increased levels of leukotrienes have been reported in a number of neurological conditions, as well as in the aged brain. Although their role is mostly unclear, it is believed that they may mediate inflammatory responses in the brain and blood vessels. The drug they used, montelukast, acts by blocking leukotriene activity, being highly successful in asthma.
According to their data, montelukast seems to be able to reduce the levels of inflammatory molecules in the brain, restore the blood-brain barrier’s integrity and increase neurogenesis in the brain of aged rats. As a consequence, montelukast treatment also restores cognitive function in the old animals.
Montelukast seems to be able to cross the blood-brain barrier and it had previously been shown to have a protective effects in animal models of neurodegenerative diseases, including Huntintgon’s and Alzheimer’s disease, as well as in induced loss of memory function, spinal cord and brain injuries and stroke, decreasing cognitive and structural deficits.
Here, they showed that this anti-asthma drug can reduce age-associated changes, improving learning and memory in old rats, reducing the inflammation-induced activation of glial cells in the brain, and restoring neurogenesis in the hippocampus of old rats most likely by targeting leukotriene actions in the brain.
It remains to be determined if a similar effect will be observed in humans, both in healthy aged humans and in the context of neurological and neurodegenerative diseases, but these results are promising.
References
Cavus G, Altas M, Aras M, Ozgür T, Serarslan Y, Yilmaz N, Sefil F, & Ulutas KT (2014). Effects of montelukast and methylprednisolone on experimental spinal cord injury in rats. European review for medical and pharmacological sciences, 18 (12), 1770-7 PMID: 24992621
Kumar A, Prakash A, Pahwa D, & Mishra J (2012). Montelukast potentiates the protective effect of rofecoxib against kainic acid-induced cognitive dysfunction in rats. Pharmacology, biochemistry, and behavior, 103 (1), 43-52 PMID: 22878042
Lai J, Mei ZL, Wang H, Hu M, Long Y, Miao MX, Li N, & Hong H (2014). Montelukast rescues primary neurons against A?1-42-induced toxicity through inhibiting CysLT1R-mediated NF-?B signaling. Neurochemistry international, 75, 26-31 PMID: 24879954
Marschallinger J, Schäffner I, Klein B, Gelfert R, Rivera FJ, Illes S, Grassner L, Janssen M, Rotheneichner P, Schmuckermair C, Coras R, Boccazzi M, Chishty M, Lagler FB, Renic M, Bauer HC, Singewald N, Blümcke I, Bogdahn U, Couillard-Despres S, Lie DC, Abbracchio MP, & Aigner L (2015). Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug. Nature communications, 6 PMID: 26506265
Saad MA, Abdelsalam RM, Kenawy SA, & Attia AS (2015). Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats. Neurochemical research, 40 (1), 139-50 PMID: 25403620
Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, Fainberg N, Ding Z, Eggel A, Lucin KM, Czirr E, Park JS, Couillard-Després S, Aigner L, Li G, Peskind ER, Kaye JA, Quinn JF, Galasko DR, Xie XS, Rando TA, & Wyss-Coray T (2011). The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature, 477 (7362), 90-4 PMID: 21886162
Villeda SA, Plambeck KE, Middeldorp J, Castellano JM, Mosher KI, Luo J, Smith LK, Bieri G, Lin K, Berdnik D, Wabl R, Udeochu J, Wheatley EG, Zou B, Simmons DA, Xie XS, Longo FM, & Wyss-Coray T (2014). Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nature medicine, 20 (6), 659-63 PMID: 24793238
Wang L, Du C, Lv J, Wei W, Cui Y, & Xie X (2011). Antiasthmatic drugs targeting the cysteinyl leukotriene receptor 1 alleviate central nervous system inflammatory cell infiltration and pathogenesis of experimental autoimmune encephalomyelitis. Journal of immunology (Baltimore, Md. : 1950), 187 (5), 2336-45 PMID: 21804021
Yu GL, Wei EQ, Zhang SH, Xu HM, Chu LS, Zhang WP, Zhang Q, Chen Z, Mei RH, & Zhao MH (2005). Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. Pharmacology, 73 (1), 31-40 PMID: 15452361
Can An Anti-Asthma Drug Rejuvenate the Brain?
Why are we below the bid
Trump is pro pharma. he said he would get the fda to move faster on drug approval
If it goes there i and most investors would be very happy.
Do you think all this interest may pave the way for an interested party buyout. Or might intelgenx resist such a buyout so early in the game, till more development demands a greater price. They seem to be onto something of the future with their film.
Some people are short and easy to figure out. Do your own DD. This company is under valued. That is my opinion.
I believe when montelukast shows efficacy in phase 2, stock price will reach 5.
In summary, we demonstrate for the first time the possibility of using montelukast to functionally rejuvenate the aged but otherwise healthy brain. Oral treatment with montelukast restored learning and memory in old rats, which was significantly impaired in comparison to young animals. Considering the various beneficial effects of montelukast on CNS functions in different animal models, this illustrates that leukotriene receptors and their underlying signalling mechanisms might contribute to the development of many neurological deficits, and that montelukast, by targeting these mechanisms, might be able to modulate and to improve a number of neurological functions in various CNS diseases.
Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug
Julia Marschallinger, Iris Schäffner, Barbara Klein, Renate Gelfert, Francisco J. Rivera, Sebastian Illes, Lukas Grassner, Maximilian Janssen, Peter Rotheneichner, Claudia Schmuckermair, Roland Coras, Marta Boccazzi, Mansoor Chishty, Florian B. Lagler, Marija Renic, Hans-Christian Bauer, Nicolas Singewald, Ingmar Blümcke, Ulrich Bogdahn, Sebastien Couillard-Despres et al.
AffiliationsContributionsCorresponding author
Nature Communications 6, Article number: 8466 doi:10.1038/ncomms9466
Received 09 December 2014 Accepted 24 August 2015 Published 27 October 2015
The company has us shareholders in mind. Not something you could say about most bios. As well horst is in it for a tidy retirement. That is why you might see a buyout before all comes to fruition
Very encouraging article. The strong team created will bring big things for this small company in my opinion. Very bullish article.
Otc manipulation on a thinly traded stock. One of these days it will explode upwards.
the climb for oncs has started. russel index friday. yeshua be with all. good health.
higher institutional ownership.
Not anymore
Shareholders
- Avtar S. Dhillon, MD 4.17%
- Heights Capital Management, Inc. 3.63%
- Sabby Capital LLC 3.45%
- Punit S. Dhillon 2.36%
- Veronica Vallejo, CPA 0.31%
- James M. DeMesa MD, MBA 0.26%
looking forward for some provocative holders.
will it be public in the future under holdings
why is that if i may ask
MARKET REPORT: Healthy interest in Inovio Pharmaceuticals's future as big pharma groups sniff around
By GEOFF FOSTER FOR THE DAILY MAIL
PUBLISHED: 21:16 GMT, 4 June 2015 | UPDATED: 21:16 GMT, 4 June 2015
54
shares
2
View comments
Medical experts this week told us that immunotherapy, which trains the immune system to attack cancerous cells, could replace chemotherapy as the standard treatment for cancer within the next five years.
The disease continues to kill people the world over and drug companies, big and small, continue to invest millions in research and development in the hope a magic cure could one day be found.
Should that ever happen, the lucky company would be worth an absolute fortune.
Treatments: Inovio Pharmaceuticals advanced 3 per cent to $8.88 on industry gossip that leading pharma groups were sniffing around
+1
Treatments: Inovio Pharmaceuticals advanced 3 per cent to $8.88 on industry gossip that leading pharma groups were sniffing around
In the meantime, anyone with a potential blockbuster cancer treatment looks vulnerable and possible fodder for one of the major drug groups.
Inovio Pharmaceuticals advanced 3 per cent to $8.88 on industry gossip that leading pharma groups were sniffing around. Indeed, speculation is rife that GlaxoSmithKline, 26p cheaper at 1411.5p, has had an $18 (£11.70) a share cash offer already rejected by the Inovio board. With rivals Roche, Bristol Myers and Merck all believed to be interested, analysts reckon the eventual take-out price could be nearer $30 (£19.50) a share.
RELATED ARTICLES
Previous
1
Next
Traders work on the floor of the New York Stock Exchange August 4, 2011. U.S. stocks resumed their downward march on Thursday after a one-day reprieve with all three major indexes down more than 1 percent as a labor market report added to recent evidence the economy has lost momentum.
REUTERS/Brendan McDermid (UNITED STATES - Tags: BUSINESS)
FTSE CLOSE: Footsie stays in doldrums as US markets react to...
Turmoil on Europe's financial markets as deadline day for...
SHARE THIS ARTICLE
Share
Inovio has a lot of DNA vaccine candidates in its pipeline, but the most advanced is VGX-3100 for cervical dysplasia, a cause of cervical cancer. Phase 2 trial results were promising enough that Inovio plans to usher it into phase 3 trials next year.
Ahead of today’s deadline for Greece’s payment of €300million (£220million) to the IMF and the release of crucial US non-farm employment numbers, it was no real surprise to see fund managers lock in some profits.
The fragile Footsie lost 112 points before closing 91.22 points down at 6859.24, while the FTSE 250 shed 173.04 points to 18090.42. Wall Street didn’t help, falling 110 points at the outset after the IMF warned that the US Federal Reserve should delay an increase in interest rates until the first half of 2016. It believes that rates should not rise until there are signs of a pick-up in wages and inflation.
B&Q retailer Kingfisher resisted the malaise, climbing 9.8p to 377.9p after Bank of America Merrill Lynch upgraded to neutral from underperform. The broker reckons trading at B&Q is improving and its Screwfix operation is powering ahead.
Buying ahead of Wednesday’s first-quarter trading update helped J Sainsbury edge up 0.5p to 250.3p. The price war among UK supermarkets in order to combat the growing challenges from the likes of Aldi and Lidl has put pressure on margins and profits.
Moneysupermarket.com led FTSE 250 constituents lower, closing 30.3p down at 275.8p. Investors did not like hearing that energy watchdog Ofgem will probe price comparison sites to see if two or more firms providing a support service for the energy industry have broken competition law.
Zoopla, which completed on Wednesday the £190million acquisition of uSwitch, a provider of comparisons of gas and electricity suppliers, lost 14.6p to 260p.
Still drawing strength from a decision to sell its parking and online payment processing units and return cash to shareholders, PayPoint advanced 46p further to 1070p. The year’s low was 779.82p on May 6.
Punters chased betting shop group Ladbrokes up to 128p on growing speculation of a possible 175p-a-share cash bid from Paddy Power – €0.14 easier at €79.56 – before the shares closed 3.2p better at 125.5p.
Support services and plant hire company VP soared 59.5p to 734.5p on record annual results. Pre-tax profits rose 33 per cent to £26.8million on revenues 12 per cent higher at £205.6million. The dividend is hiked 18 per cent to 16.5p a share.
Dog of the day was Scisys which crashed 24.25p or 30 per cent to 58p on a profits warning. The complexity of a major contract in its Enterprise Solutions and Defence division will mean a big shortfall in profits for 2015.
Pressure Technologies also came a cropper, falling 75p or 28 per cent to 195p after warning that results for the current and next financial year would be ‘materially lower’ than market forecasts. The engineering solutions provider admitted it has experienced a further slowdown over the past few weeks in the release of capital projects in the oil and gas market.
Former cash shell Guscio edged up to 7p after announcing its Sportsdata Ltd company has signed a deal with the charitable arm of Charlton Athletic FC.
Under the deal, Sportsdata, in which Guscio owns a 30 per cent stake, has agreed with the club’s community trust to promote, market and deliver Skills2Achieve programmes to local schools.
Backers of Guscio include chairman and 7.4 per cent shareholder Richard Thompson, and entrepreneur Nigel Wray, who owns 7.8 per cent.
Contract news lifted Crimson Tide 12 per cent to 2.1p. The developer of enterprise mobile solutions has won a four-year contract with an undisclosed customer to provide proof of delivery information across London, worth a minimum of £218,000 over the period.
possible spillover
Read more: http://www.thisismoney.co.uk/money/markets/article-3111580/MARKET-REPORT-Healthy-Inovio-Pharmaceuticals-s-future.html#ixzz3cBKbPGdJ
Follow us: @MailOnline on Twitter | DailyMail on Facebook
Still don't know the buyer.
How many institutions will be buying Friday?